Pharmaceutical Executive July 21, 2025
Dr. Ben Zeskind, CEO of Immuneering, discusses the new approach his company is taking to oncology.
Dr. Ben Zeskind, CEO and co-founder of Immuneering, spoke with Pharmaceutical Executive about his company’s approach to treating cancer. Based on the company’s research, he believes that treating tumors at a slower and steadier pace may produce more reliable results that also avoid subjecting patients to some of the worst side effects that often accompany cancer treatment.
Pharmaceutical Executive: Can you discuss the history of Immuneering?
Dr. Ben Zeskind: We started the company 17 years ago with the goal of helping cancer patients live longer and longer until they eventually outlive their disease. We can transform cancer into something that’s more of a manageable condition,...
Today's Sponsors
Today's Sponsor